The prophylaxis treatment of cytomegalovirus is also increasing due to its effective and safe treatment. The U.S. Food and Drug Administration (USFDA) and European Medicines Agency (EMA) are supporting the cytomegalovirus infection therapeutics pipeline by encouraging the drug development process through different types of designations. The pipeline is being driven by different factors such as increasing awareness regarding the cytomegalovirus infection treatment, high demand for safe and effective medications, technological advancements and increasing prevalence of the cytomegalovirus.

Explore Report at: https://www.psmarketresearch.com/market-analysis/cytomegalovirus-infection-therapeutics-pipeline-analysis

According to Centers for Disease Control and Prevention, cytomegalovirus, is a common virus that infects people of all ages. Over half of adults by age 40 have been infected with cytomegalovirus. Once cytomegalovirus is in a person's body, it stays there for life and can reactivate., with a major number of people infected with cytomegalovirus showing no signs or symptoms of the disease. However, cytomegalovirus infection can cause serious health problems for people with weakened immune systems, as well as babies infected with the virus before they are born. When a baby is born with cytomegalovirus infection, it is called congenital cytomegalovirus infection. About one out of every 150 babies are born with congenital cytomegalovirus infection. However, only about one in five babies with congenital cytomegalovirus infection will be sick from the virus or will have long-term health problems. In some cases, infection in healthy people can cause mild illness that may include fever, sore throat, fatigue and swollen glands.

Request for Table of Content at: https://www.psmarketresearch.com/market-analysis/cytomegalovirus-infection-therapeutics-pipeline-analysis/toc-sample

Some of the companies having a pipeline of cytomegalovirus infection therapeutics include Biotest AG, Merck & Co., Inc., Chimerix Inc., Astellas Pharma, Inc., CSL Behring, Cell Medica Ltd., GlaxoSmithKline plc, Pfizer, Inc., F. Hoffmann-La Roche and AstraZeneca plc.